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TO THE EDITOR
Despite consensus that intense, inter-
mittent UV exposure is a major mela-
noma risk factor, the role of DNA repair
in melanoma pathogenesis remains
controversial. UV-characteristic cyclo-
butane–pyrimidine dimers and pyrimi-
dine–pyrimidone 6,4-photoproducts are
absent in most melanomas, and many
frequently encountered mutations in
melanoma, such as BRAF c.1799 T-A,
are not characteristic UV signature
mutations (Davies et al., 2002).
We set out to explore the role of
DNA repair in melanoma by micro-
array analysis of expression of DNA
repair genes in melanoma and non-
melanoma skin cancer (NMSC). Our
study population included 16 primary
cutaneous melanomas (PCMs), 11
squamous cell carcinomas (SCCs), and
15 basal cell carcinomas (BCCs). PCMs
included two melanomas in situ, two
thin (o1 mm Breslow depth, measured
from top of stratum granulosum to
deepest portion of tumor), three inter-
mediate thickness (1–4 mm), and nine
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Figure 1. Fanconi anemia, but not nucleotide-excision repair (NER), genes are transcriptionally upregulated in melanoma compared with normal skin
and non-melanoma skin cancer (NMSC). (a) Microarray analysis of Fanconi anemia and NER gene expression in metastatic melanoma and squamous
cell carcinoma (SCC). Green and red represent decreased and increased expression relative to control, respectively. Color intensity is proportional to expression
level up to a 4-fold difference from control. Middle row shows combined expression of FANCD2þ FANCL relative to normal skin; dark brown, medium tan,
and orange denote 25–50% greater, 50–100% greater, and more than 100% greater than normal, respectively. (b) DNA microarray analysis of Fanconi
anemia (FA) and NER genes in primary cutaneous melanoma (PCM). (c) Quantitative reverse transcription PCR analysis of FANCD2 expression in
PCM versus NMSC. FANCD2 expression levels were normalized to b-actin mRNA levels. Vertical bars represent standard error. MIS, melanomas in situ.
Abbreviations: BCC, basal cell carcinoma; FA, Fanconi anemia; MM, metastatic melanoma; NER,
nucleotide excision repair; NMSC, non-melanoma skin cancer; PCM, primary cutaneous melanoma;
SCC, squamous cell carcinoma
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thick melanomas (44 mm). A total of
40 metastatic melanoma (MM) samples
were also analyzed (Supplementary
Table S1 online).
The Fanconi anemia (FA) repair
pathway is the primary cellular mecha-
nism for addressing DNA damage
related to crosslinks, alkylation, and
stalled replication forks (Kee and D’An-
drea, 2010). We found that expression
of FA genes is significantly elevated in
MM compared with normal skin. The
most melanoma-specific signature was
provided by the aggregate expression
of FANCL and FANCD2. Combined
FANCD2–FANCL expression was at
least 50% greater than normal skin in
35 of 40 MM samples, but in none of
the BCCs or SCCs (Figure 1a, Supple-
mentary Table S3 online). In contrast,
no nucleotide-excision repair (NER)
genes were significantly upregulated
in MM. Expression of XPA, XPE, XPG,
and RAD23B were significantly de-
creased in MM (Figure 1a, Supplemen-
tary Tables S2 and S4 online). This
observation is consistent with the
high incidence of melanoma in xero-
derma pigmentosum patients with
defects in the NER pathway.
We next examined the expression
levels of DNA repair genes in PCM.
When segregated according to Breslow
depth, a stepwise increase in FA gene
expression was noted with increasing
melanoma thickness (Figure 1b, Sup-
plementary Tables S5 and S6 online). In
melanomas in situ, only one FA gene,
FANCN, was overexpressed; in inter-
mediate-thickness melanomas, three
genes (FANCB, G, and L) were over-
expressed. In thick melanomas, nine
FA genes were broadly overexpressed,
including FANCA, B, C, D1, D2, G, I, L,
and N. NER expression was not signi-
ficantly increased in PCM.
We then sought to confirm our DNA
microarray findings by quantitative
reverse transcription PCR analysis of
randomly selected PCM and NMSC.
Consistent with the microarray results,
normalized mRNA levels of the key
downstream mediator FANCD2 were
significantly higher in eight PCM than
in nine NMSC (P¼ 0.0001, Figure 1c).
Furthermore, there was a trend toward
association between Breslow depth and
FANCD2 expression level detected by
quantitative reverse transcription PCR
(data not shown).
To assess changes in FA expression
at the protein level, we analyzed
four randomly selected melanomas
and four NMSCs by immunohistochem-
istry for expression of FANCD2. These
included two thin and two inter-
mediate-thickness PCMs, as well as
three SCCs and one BCC (Supplemen-
tary Table S7 online). When comparing
PCMs to NMSCs, 45% of melanoma
cells had intense homogenous-to-
granular nuclear staining (Figure 2)
versus 4.8% in NMSC (P¼0.029).
When comparing PCMs of differing
depth, we found increased FANCD2
staining with increased Breslow thick-
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Figure 2. Strong nuclear FANCD2 protein expression is observed in primary melanoma but not
non-melanoma skin cancer (NMSC). Paraffin-embedded tumors were immunostained with 1:50
anti-FANCD2 (H-300; sc28194, Santa Cruz, Santa Cruz, CA) and then biotinylated anti-rabbit antibody
(Vector Laboratories, Burlingame, CA). (a) Photomicrographs of FANCD2 protein expression in
primary cutaneous melanoma (PCM; left panels) and NMSC (right panels). Breslow thickness is shown
for each PCM. Black bars at lower right of each panel indicate 50 mm. (b) Percentage of PCM and
NMSC cells with positive nuclear staining for FANCD2 by immunohistochemistry. Numbers associated
with each PCM on the horizontal axis represent Breslow thickness. BCC, basal cell carcinoma;
SCC, squamous cell carcinoma.
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ness. The two thin PCMs displayed
nuclear staining of FANCD2 in 13 and
31% of cells, respectively, compared
with 60 and 75% in intermediate-thick-
ness melanomas. No significant eleva-
tion of markers of S-phase progression,
including Ki-67 labeling index (data
not shown) or transcript levels of
cyclin A, cyclin E, or histone H3, were
found in melanoma compared with
NMSC (Supplementary Table S8 on-
line). Thus, we believe that increased
FA gene expression in melanoma was
not simply due to increased prolifera-
tive index.
Although increased gene expression
does not necessarily imply FA pathway
hyperactivation, three lines of evidence
suggest this is likely the case. First,
given that FANCD2–FANCI nuclear
complexes are an established hallmark
of FA pathway activation (Kee and
D’Andrea, 2010), the increased homo-
genous and granular nuclear staining
we observed for FANCD2 protein in
melanoma appears consistent with FA
activation. Second, FA pathway activity
correlates closely with level of FA gene
transcripts (Vaughn et al., 1996; Taniguchi
et al., 2002; Hoskins et al., 2008). Finally,
FA activation through overexpression
of FA pathway constituents has been
reported to confer cellular resistance to
DNA damage (Hazlehurst et al., 2003;
Chen et al., 2007).
These reports suggest that the FA
pathway may function in oncogenesis
in addition to its previously implicated
role of tumor suppressor (Condie et al.,
2002). Consistent with this hypothesis,
FANCC knockout mice are deficient
in STAT-1-mediated IFN-g signaling
(Pang et al., 2000), a pathway that
may promote UVB-mediated melano-
magenesis (Zaidi et al., 2011). In addi-
tion, activation of the FA pathway
could provide resistance to increased
endogenous DNA damage typically
seen in oncogenic states (Nitta et al.,
2010) and confer survival advantage to
melanoma cells. Further supporting this
hypothesis, activation of the FA path-
way has been associated with resis-
tance to a variety of DNA-damaging
agents including 1,3-bis[2-chloroethyl]-
1-nitroso-urea and temozolomide
(Chen et al., 2007), the tumoricidal
effect of which is synergistically in-
creased by bortezomib, a FA pathway
inhibitor (Jacquemont and Taniguchi,
2007).
Recent studies have shed light on
possible mechanisms of FA gene upre-
gulation during melanoma patho-
genesis. For instance, E2F activates the
FANCD2 gene by binding consensus
promoter response elements (Hoskins
et al., 2008). Similarly, NF-kB binds
and activates the FANCD2 promoter
(Yarde et al., 2009) as well as mediates
nuclear localization of FANCD2 (Ma
et al., 2009). Finally, p53 has been
shown to bind the FANCC promoter
and upregulate FANCC transcription
(Liebetrau et al., 1997). Aberrant regu-
lation of such transcription factors
during melanomagenesis may account
for increased FA gene transcription
that is disassociated from cell-cycle-
dependent regulation.
In summary, we have found that FA
DNA repair genes are transcriptionally
upregulated in melanoma. Further-
more, increased FA gene expression
correlates with increased Breslow thick-
ness. In the context of the broader
literature, our results suggest that activa-
tion of the FA pathway could contribute
to melanomagenesis and resistance to
chemotherapy. As such, we propose
that FA pathway inhibition constitutes
a potential therapeutic strategy for
melanoma.
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